However, TGF-β blockade using a neutralizing antibody has been shown to worsen proteinuria in murine diabetic nephropathy and rat puromycin aminonucleoside nephropathy [2,3], implicating a complex role in renal disease progression. Here, TGFB1 is linked to kidney disorder.